Identification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2
- 1 August 2015
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 75 (15) , 3139-3146
Abstract
The discovery of oncogenic driver mutations and the subsequent developments in targeted therapies have led to improved outcomes for subsets of lung cancer patients. The identification of additional oncogenic and drug-sensitive alterations may similarly lead to new therapeutic approaches for lung cancer. We identify and characterize novel FGFR2 extracellular domain insertion mutations and demonstrate that they are both oncogenic and sensitive to inhibition by FGFR kinase inhibitors. We demonstrate that the mechanism of FGFR2 activation and subsequent transformation is mediated by ligand-independent dimerization and activation of FGFR2 kinase activity. Both FGFR2-mutant forms are predominantly located in the endoplasmic reticulum and Golgi but nevertheless can activate downstream signaling pathways through their interactions with fibroblast growth factor receptor substrate 2 (FRS2). Our findings provide a rationale for therapeutically targeting this unique subset of FGFR2-mutant cancers as well as insight into their oncogenic mechanisms. Cancer Res; 75(15); 3139–46. ©2015 AACR.Keywords
All Related Versions
This publication has 34 references indexed in Scilit:
- The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastomaJournal of Clinical Investigation, 2013
- Transforming Fusions of FGFR and TACC Genes in Human GlioblastomaScience, 2012
- High-Throughput Detection of Actionable Genomic Alterations in Clinical Tumor Samples by Targeted, Massively Parallel SequencingCancer Discovery, 2012
- Differential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplificationBritish Journal of Cancer, 2011
- Inhibitor-Sensitive FGFR1 Amplification in Human Non-Small Cell Lung CancerPLOS ONE, 2011
- The Neuroblastoma-Associated F1174L ALK Mutation Causes Resistance to an ALK Kinase Inhibitor in ALK-Translocated CancersCancer Research, 2010
- Novel mutant-selective EGFR kinase inhibitors against EGFR T790MNature, 2009
- Drug-sensitiveFGFR2mutations in endometrial carcinomaProceedings of the National Academy of Sciences, 2008
- Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromesOncogene, 2007
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004